DPP4 Inhibition & Beta Cell Function

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

March 16, 2018

Study Completion Date

March 16, 2018

Conditions
Healthy
Interventions
DRUG

Active Comparator: Sitagliptin

Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).

DRUG

Placebo Comparator - No Sitagliptin

Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).

Trial Locations (1)

27707

Leslie Willis, Durham

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

David D'Alessio, M.D.

OTHER

NCT02683187 - DPP4 Inhibition & Beta Cell Function | Biotech Hunter | Biotech Hunter